CRMD
What one share of Cormedix holds
Pharmaceutical Preparations
Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis
Cormedix’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.06 |
|---|---|
| Profit | $2.05 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | $2.74 |
| Cash and investments | $3.31 |
| Book value | $5.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$28.70 | $0.03 | −$9.70 | — | — |
| 2011 | — | −$14.60 | $0.00 | −$13.80 | — | $2.90 |
| 2012 | — | −$7.40 | $0.00 | −$5.00 | — | −$0.70 |
| 2013 | — | −$17.20 | $0.06 | −$6.60 | — | — |
| 2014 | — | −$23.90 | $0.03 | −$7.40 | — | $4.00 |
| 2015 | — | −$14.51 | $0.01 | −$10.00 | — | $23.64 |
| 2016 | — | −$16.23 | $0.04 | −$14.70 | — | $11.02 |
| 2017 | — | −$2.99 | $0.01 | −$2.61 | — | $0.50 |
| 2018 | — | −$1.51 | $0.00 | −$1.33 | — | $0.23 |
| 2019 | — | −$1.80 | $0.00 | −$0.62 | — | $0.92 |
| 2020 | — | −$0.77 | $0.00 | −$0.77 | — | $1.32 |
| 2021 | — | −$0.75 | $0.04 | −$0.60 | — | $1.65 |
| 2022 | — | −$0.74 | $0.01 | −$0.61 | — | $1.29 |
| 2023 | — | −$0.91 | $0.01 | −$0.76 | — | $1.28 |
| 2024 | $0.74 | −$0.30 | $0.00 | −$0.86 | — | $1.31 |
| 2025 | $3.88 | $2.03 | $0.03 | $2.15 | — | $5.11 |